Innovative collaboration further expands Sofra™ platform

Highlights

- **First results from InhaTarget Therapeutics study**
- **Novel lung delivery method shows Sofra™ versatility**
- **Data confirms anti-inflammatory properties of Sofra drug in lung**

Sydney, 27 April 2026: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce first study results from a European company testing Sofra™ technology platform assets.

Belgium's InhaTarget Therapeutics is developing innovative treatments for lung-related diseases via a unique inhalation-based delivery system. The company has expertise in drug formulation, inhalation delivery, immunology, preclinical development and clinical operations.

Lung inflammatory diseases represent a significant and growing global health burden, affecting hundreds of millions of people worldwide. Substantial unmet medical needs remain, particularly in achieving durable control of airway inflammation and in patients with inadequate responses to current therapies. The global market for inhaled therapies was valued at approximately US$11.6 billion in 2024 and is projected to exceed US$16 billion by 2034.

Noxopharm signed a first Material Transfer Agreement with InhaTarget in October 2024, followed by a second one in May 2025 to enable the testing of a series of Sofra assets within the context of lung inflammation. During that period, InhaTarget successfully developed an optimised formulation process before evaluating the payload potential of Sofra oligonucleotides.

InhaTarget focuses on delivering innovative therapies through inhalation, marking a new addition to the ways in which Noxopharm's oligonucleotides can be delivered to target tissues such as the lungs.

This delivery method is based on the use of InhaTarget's proprietary lipid nanoparticles (LNPs), which differ from other delivery methods tested under previously announced MTAs where antibodies and target-specific proteins were successfully weaponised with Sofra candidates (see BioRay and Tezcat announcements respectively).

Using the immune-modulating oligonucleotides from Noxopharm's Sofra platform, InhaTarget performed a series of studies that showed successful encapsulation with an optimized LNP formulation, and an over 75% reduction in lung inflammation in an animal model.

Figure: Pulmonary delivery of Noxopharm's TLR7/8-inhibiting oligonucleotides using InhaTarget's inhalable LNP significantly reduces lung inflammation in a mouse model



Lung inflammation was induced in mice using a TLR7/8 agonist (R848) and assessed by five inflammatory biomarkers. Airway delivery of Noxopharm's TLR7/8-inhibiting oligonucleotides formulated with InhaTarget's lung-targeting LNP resulted in a significant reduction in inflammatory marker levels, with an average decrease of 77%.

*Level of lung inflammation (%): Levels of five inflammatory biomarkers were normalized to the untreated group, and the mean value across all five biomarkers is shown; Nox-Oligo: Noxopharm's TLR7/8-inhibiting oligonucleotide; Inha-LNP: InhaTarget's lung-targeting LNP; ****p < 0.0001; n = 7.*

InhaTarget CEO Frédéric De Coninck said: "We are very pleased to be working with Noxopharm. This novel and highly innovative platform represents a strong fit with our delivery system. We look forward to expanding our collaboration in the coming months and aim to advance this technology toward clinical trials."

Noxopharm CEO Dr Oliver Laczka said: "This project offers yet another delivery method for our versatile oligonucleotides, and another tissue type as well. Our Sofra technology has broad relevance to many diseases, and we will continue expanding the platform while working with pioneering partners like InhaTarget to showcase Sofra's multiple use cases."

-ENDS-

About the Sofra technology platform

Developed from a breakthrough discovery in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as enhancing RNA therapeutics and vaccines.

Sofra technology has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

About InhaTarget Therapeutics, SRL

InhaTarget is a clinical-stage company dedicated to the (co-)development of innovative and targeted formulations for inhalation, including dry powders for inhalation (DPI) and liquid forms, to improve the treatment of severe and/or chronic respiratory diseases. The company specializes in early development and clinical validation, with an initial focus on lung cancer. For more information, visit www.inhatarget.com.

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.